Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2009-04-27 Board/Management Inform…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA announces today the strengthening of its management team with the appointment of Marcel Rozencweig, MD, as Senior Vice President in charge of clinical and regulatory strategy
Board/Management Information Classification · 98% confidence The document is a press release dated April 27, 2009, announcing the appointment of a new Senior Vice President, Dr. Marcel Rozencweig, to lead clinical and regulatory strategy. This content directly relates to changes in the company's senior management team. Based on the provided definitions, the category 'Board/Management Information' (Code: MANG) is the most appropriate classification for announcements regarding changes in senior management.
2009-04-27 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce sa participation prochaine à BioCapital Europe, C,F&B Smallcap Event et BioEquity Europe
Report Publication Announcement Classification · 99% confidence The document is a press release dated April 17, 2009, announcing the company's participation schedule in upcoming financial community events (conferences like BioCapital Europe, C,F&B Smallcap Event, and BioEquity Europe) occurring in April and June 2009. It also includes standard company information and a disclaimer. This type of announcement, which details future meetings with investors and the financial community, is best classified as an Investor Presentation (IP) if it were the presentation itself, or more accurately, a general announcement regarding investor relations activities. Since the document is announcing *where* the company will be meeting investors, and it is not a formal regulatory filing (like 10-K, ER, or IR), nor is it a proxy statement or dividend notice, it falls under the category of general communication aimed at investors. Given the options, 'Investor Presentation' (IP) is often used broadly for investor-facing materials, but the core function here is announcing *future* engagement dates. However, looking closely at the definitions, none perfectly capture 'Investor Event Schedule Announcement'. The closest fit among the specific codes that deal with investor communication and strategy updates is 'Investor Presentation' (IP), although it is not a presentation itself. Alternatively, since it is a press release detailing future investor engagement, it could be considered a general Regulatory Filing (RNS) if it doesn't fit elsewhere. Given that it is a proactive communication detailing future investor engagement, and not a report itself, 'RPA' (Report Publication Announcement) is incorrect. 'IP' (Investor Presentation) is often used for materials presented *at* events. Since this is an announcement *about* attending events, and it's not a core financial report, 'RNS' (Regulatory Filings - the fallback for miscellaneous announcements) is a strong candidate. However, in many databases, announcements detailing future investor meetings are grouped with investor relations materials. Given the context of financial reporting, this is a communication directed at the investment community about future interactions. I will classify this as 'RNS' as it is a general press release announcing non-mandatory, forward-looking investor engagement schedules, which doesn't fit the more specific financial report codes.
2009-04-17 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces it will participate to the following analyst and investor conferences in the coming weeks: BioCapital Europe, C,F&B Smallcap Event and BioE
Report Publication Announcement Classification · 99% confidence The document is a press release dated April 17, 2009, announcing the company's schedule for participating in upcoming analyst and investor conferences (BioCapital Europe, C,F&B Smallcap Event, BioEquity Europe). This type of announcement, which informs the financial community about future investor engagement events, is best classified as an Investor Presentation (IP) related activity or, more broadly, a general update for investors. Since there is no specific category for 'Conference Schedule Announcement,' and it is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA), it falls under the general category of investor communication. However, given the options, the content is directly related to investor relations activities and scheduling meetings, which often accompanies or precedes investor presentations. Since it is an announcement about future investor engagement rather than the presentation material itself, and it is not a standard regulatory filing like a DIRS or MRQ, the most fitting category among the specific options is 'Investor Presentation' (IP) as it pertains to investor outreach, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the focus on upcoming meetings with analysts and investors, 'Investor Presentation' (IP) is the most contextually relevant choice, as these events are the primary venue for delivering investment information, even if this document is just the schedule.
2009-04-17 English
Innate Pharma SA (la « Société »), société biopharmaceutique spécialisée dans le développement de médicaments immuno-thérapeutiques innovants pour le traitement du cancer et d’autres maladies graves,
Annual Report Classification · 95% confidence The document is a comprehensive financial results announcement for Innate Pharma for the fiscal year 2008. It includes detailed financial tables (consolidated income statement), management commentary on operational results, R&D progress, and future outlook. While it is an announcement, it contains substantive financial data and analysis for the full fiscal year, distinguishing it from a simple report publication announcement (RPA). Given it covers the full fiscal year performance, it aligns with the definition of an Annual Report (10-K) or a comprehensive financial report. FY 2008
2009-02-27 French
Innate Pharma S.A. (the “Company”), a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases, reports today its financial results f
Earnings Release Classification · 99% confidence The document explicitly states it reports 'financial results for 2008' and provides a detailed 'consolidated income statement for the 12-month period ending December 31, 2008,' comparing it with 2007 and 2006. This structure, covering a full fiscal year with comprehensive financial tables and management discussion, is characteristic of an Annual Report. Although the text mentions 'Unaudited consolidated financial statements are attached to this press release,' the document itself contains the core financial narrative and data, making it function as the primary annual disclosure. Given the comprehensive nature covering the full year, it aligns best with the Annual Report (10-K) definition, even if it might be presented as a press release summarizing the 10-K filing. The length (56,295 chars) also supports it being a full report rather than just a brief announcement (RPA/ER). FY 2008
2009-02-27 English
Innate Pharma annonce l’atteinte d’un paiement d’étape pré-clinique pour un nouveau projet d’anticorps monoclonal développé en collaboration avec Novo Nordisk A/S
Regulatory Filings Classification · 94% confidence The document is a press release dated February 12, 2009, announcing a pre-clinical milestone payment achieved by Innate Pharma from its collaboration with Novo Nordisk A/S regarding a monoclonal antibody project (IPH 24). The text details the advancement of a drug candidate, the associated payment, and the responsibilities under the collaboration agreement. This type of announcement, which communicates a specific, material event (like a milestone payment or R&D progress) outside of routine financial reporting periods (like 10-K or IR), is typically classified as an Earnings Release (ER) if it contains key financial/operational highlights, or a Regulatory Filing (RNS) if it's a general market announcement. Since it is a specific, material corporate event announcement (milestone achieved and payment received) that is not a full financial report, it fits best under the 'Earnings Release' category (ER) as it releases key operational/financial progress, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the content is a specific, material corporate update, ER is often used for such press releases detailing operational achievements that impact future earnings potential, even if not strictly quarterly results. However, since it is not explicitly an 'Earnings Release' for a period, and it is a general corporate announcement about a partnership milestone, RNS (Regulatory Filings - the fallback for miscellaneous announcements) is a safer classification, though ER is plausible if interpreted broadly as a 'results' announcement. Given the options, and that it is a formal announcement of a specific corporate event/achievement, I will lean towards RNS as the most appropriate general regulatory announcement category, as it is not a formal financial report (10-K, IR) or a dedicated earnings summary (ER). The document length is substantial (8001 chars), ruling out RPA based on the 'MENU VS MEAL' rule.
2009-02-12 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.